Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

BCRX BioCryst Pharmaceuticals Inc

6,46

0,00 (0,00%)

Vor Marktöffnung

Zuletzt aktualisiert: 10:00:02

Verzögert um 15 Minuten

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Click Here for more BioCryst Pharmaceuticals Charts.

BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
Von Jun 2023 bis Jun 2024

Click Here for more BioCryst Pharmaceuticals Charts.

News BioCryst Pharmaceuticals Inc

BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment
Sonntag 2 Juni 2024 (1 Tag vor) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 31 Mai 2024 (3 Tage vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 29 Mai 2024 (5 Tage vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 22 Mai 2024 (2 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 22 Mai 2024 (2 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 15 Mai 2024 (3 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 15 Mai 2024 (3 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 15 Mai 2024 (3 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 15 Mai 2024 (3 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 15 Mai 2024 (3 Wochen vor) • Edgar (US Regulatory)

BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology
Dienstag 14 Mai 2024 (3 Wochen vor) • GlobeNewswire Inc.

ORLADEYO® (berotralstat) Approved in Mexico
Montag 13 Mai 2024 (3 Wochen vor) • GlobeNewswire Inc.

Weitere BioCryst Pharmaceuticals Inc News-Artikel

PIMCO Income Opportunity

DMM: Governance

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen